Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rentokil Initial plc due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by January 27, 2025 [2][4]. Company Overview - Rentokil Initial plc is a publicly traded company on the NYSE under the ticker RTO [2]. - The company has faced significant challenges in integrating Terminix, which has negatively impacted its business operations and organic revenue growth in North America [4][7]. Allegations and Financial Impact - The complaint alleges that Rentokil made false or misleading statements regarding its integration of Terminix, failing to disclose execution challenges and disruptions [4]. - Following the release of disappointing financial results for Q1 2024, Rentokil's stock price fell over 9%, from $28.25 to $25.61 per ADS [5][6]. - On September 11, 2024, Rentokil announced a revised expectation of only 1% organic revenue growth for the second half of 2024, leading to a further decline in stock price of over 21%, from $31.60 to $24.95 per ADS [7]. Legal Proceedings - Investors who suffered losses exceeding $75,000 between December 1, 2023, and September 10, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action lawsuit is open to any member of the putative class, with the ability to direct and oversee the litigation [8]. Call for Information - Faruqi & Faruqi is seeking information from whistleblowers, former employees, and shareholders regarding Rentokil's conduct [9].

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rentokil Initial Plc (“Rentokil” or the “Company”) (NYSE: RTO) in the United States District Court for the Western District of Tennessee on behalf of all persons and entities who purchased or otherwise acquired Rentokil securities between December 1, 2023 and September 10, 2024, both dates inclusive (the “Class Period”). In ...

NEW YORK, Dec. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS”) of Rentokil Initial plc (NYSE: RTO) between December 1, 2023 and September 10, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 27, 2025. SO WHAT: If you purchased Rento ...

Core Viewpoint - The Rentokil Initial plc is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, primarily related to its acquisition of Terminix Global Holdings and subsequent integration challenges [1][4]. Group 1: Lawsuit Details - The lawsuit is titled Laborers Local 235 Pension Fund v. Rentokil Initial plc, with lead plaintiff motions due by January 27, 2025 [1]. - Rentokil completed its acquisition of Terminix for $6.7 billion, which included $1.34 billion in cash and over 129 million new Rentokil American Depositary Shares (ADSs) [3]. - Allegations include false statements regarding the integration of Terminix, claiming that Rentokil faced significant execution challenges and disruptions during the integration process [4]. Group 2: Financial Impact - On April 18, 2024, Rentokil reported only 1.5% organic revenue growth in North America, below the guidance of 2% for Q1 and 2% to 4% for the full year, leading to a more than 9% drop in ADS price [5]. - A subsequent trading update on September 11, 2024, revised the expected organic revenue growth for the second half of 2024 to only 1%, causing a further decline of over 21% in ADS price [6]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Rentokil ADSs during the class period to seek appointment as lead plaintiff, representing the interests of the class [7]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in securities-related class action cases, and is recognized for securing significant monetary relief for investors [8].

NEW YORK, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rentokil Initial Plc (“Rentokil” or “the Company”) (NYSE: RTO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Rentokil ...

Lawsuit Overview - Saxena White P A has filed a securities fraud class action lawsuit against Rentokil Initial plc and certain executive officers under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 [1] - The lawsuit is on behalf of all persons and entities that purchased Rentokil American Depositary Shares (ADSs) between December 1 2023 and September 10 2024 [1] Company Background - Rentokil provides pest control hygiene and wellness services worldwide with three main business lines: Pest Control Hygiene & Wellbeing and France Workwear [2] - Rentokil is the largest global pest control services provider with North America Pest Control accounting for more than half of the Company's annual revenue [2] - Rentokil completed the acquisition of Terminix Global Holdings Inc in a transaction valued at $6 7 billion including $1 34 billion in cash and over 129 million new Rentokil ADSs [2] Allegations - Defendants made materially false and misleading statements and failed to disclose material adverse facts about the Company's business operations and prospects during the Class Period [3] - Rentokil experienced significant ongoing self-inflicted execution challenges integrating Terminix which imperiled the integration plan [3] - Rentokil and Terminix were still two separate businesses that were not yet integrated negatively impacting the Company's business and operations particularly organic revenue growth in North America [3] Financial Disclosures - Rentokil reported organic revenue growth in North America increased by only 1 5% year-over-year for the first quarter of 2024 below the Company's guidance of 2% [4] - Rentokil now expects only 1% organic revenue growth in North America for the second half of 2024 well below the Company's prior guidance [5] - The trading performance in July and August was lower than anticipated with modest disruption to organic growth from branch integration [5] Market Reaction - The price of Rentokil ADSs fell over 9% from a closing price of $28 25 per ADS on April 17 2024 to a closing price of $25 61 per ADS on April 18 2024 [4] - The price of Rentokil ADSs fell over 21% from a closing price of $31 60 per ADS on September 10 2024 to a closing price of $24 95 per ADS on September 11 2024 [5]

SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Rentokil class action lawsuit, captioned Laborers Local #235 Pension Fund v. Rentokil Initial plc, No. 24-cv-02932 (W.D. Tenn.), charges Rentokil Initial plc (NYSE: RTO) and certain of Rentokil’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rentokil class action lawsuit, please provide your information here: h ...

The stock price of Rentokil Initial plc (NYSE: RTO ) has essentially gone sideways for the last five years. In that time, the company has been profitable but there was no real story around the stock, no catalyst. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in RTO over the next 72 hours. I wrote this article ...

Key Takeaways An executive of Nelson Peltz's Trian Fund Management was named to the Rentokil Initial board. Brian Baldwin, Head of Research at Trian, will join the board as a non-executive member on Oct. 1. Trian took what it called "a significant position" in Rentokil in June, which the company said totaled 2.26% of shares outstanding. American depositary receipts (ADRs) of Rentokil Initial (RTO) gained Wednesday when the pest-control company announced that an executive from activist investor Nelson Peltz' ...

Pest control maker Rentokil Initial said Wednesday that Trian partner Brian Baldwin would join the Terminix owner's board effective next week. The company said Baldwin, who has worked at Nelson Peltz's firm since 2007, will also join the nominating and compensation committees. The accession comes three months after Trian first disclosed a roughly $400 million position in Rentokil, and two weeks after the company issued a profit warning. Rentokil has struggled since it completed its nearly $7 billion acquisi ...